MNDR

Business Context and Reporting Period

Company: Mobile-Health Network Solutions (MNDR)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Jurisdiction: Cayman Islands (Headquartered in Singapore)
Business Overview: A leading telehealth solutions provider in Singapore operating the MaNaDr ecosystem. The company offers teleconsultations, e-commerce for medical products (MaNaShop), B2B pharmaceutical sales (MaNaPharma), and corporate wellness services (MaNaCare). The platform utilizes AI-driven tools for triage and health monitoring.

Key Financial Metrics

Segment Performance: Telemedicine and other services generated $12.86 million (92.0% of revenue), while the sale of medicine and medical devices generated $1.11 million (8.0%).

Material Changes vs. Prior Period

• Revenue Growth: Driven primarily by a 88.4% increase in private sector telemedicine revenue ($12.63M vs $6.70M), offsetting a near-total collapse in public sector revenue due to the end of COVID-19 government contracts.
• Expense Surge: Operating expenses increased by $13.86 million. This was largely due to $9.12 million in share-based compensation (non-cash) related to the IPO and advisor services, and increased professional fees for the IPO.
• Liquidity Position: Cash balances increased significantly to $6.7 million following the April 2024 Initial Public Offering (IPO), which raised approximately $9.2 million in net proceeds.
• Profitability: Despite revenue growth, the company reported a net loss of $15.6 million compared to $3.2 million in the prior year, primarily due to the non-cash share-based compensation expense and increased operating costs.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Management expects telemedicine revenue from the public sector to remain negligible as Singapore's disease response levels have normalized.
• Strategic focus includes expanding the user base, integrating Generative AI for personalized care, and expanding operations into Malaysia, Indonesia, and Vietnam.
• The company intends to use remaining IPO proceeds for working capital and corporate purposes.

• Regulatory Suspension (Critical): On August 16, 2024, the Singapore Ministry of Health (MOH) directed "Manadr Clinic @Citygate" to temporarily suspend outpatient teleconsultation services under the Healthcare Services Act. Management estimates this could result in a 50-55% drop in teleconsultation cases, though they initially assessed the financial impact as immaterial.
• AI Risks: Risks associated with Generative AI integration, including data privacy, potential for incorrect medical output, and evolving regulatory landscapes.
• Internal Controls: As a newly public company, the registrant is in the process of establishing effective internal controls over financial reporting (Section 404 compliance).
• Geopolitical & FX: Operations in Vietnam and Malaysia expose the company to foreign exchange fluctuations and local regulatory changes.

Investor Verification Checklist

• MOH Suspension Impact: Verify the actual financial impact of the August 2024 suspension of Manadr Clinic @Citygate on Q1 2025 results, given the management estimate of a 50-55% drop in cases.
• Share-Based Compensation: Confirm the sustainability of the $9.12 million non-cash expense and its impact on future cash burn rates.
• Private Sector Retention: Assess the retention rate of patients converted from public sector COVID contracts to private paying users.
• Internal Controls: Review the upcoming Section 404 attestation report for any material weaknesses identified post-IPO.
• AI Deployment: Evaluate the timeline and regulatory approval status for the new Generative AI features and AI Facescan technology.